-
Could rewiring the brain’s “brakes” improve movement in Huntington’s disease?
6 min read
Latest News
-
Fixing the Recipe: Lowering a Slice of Huntingtin
8 min read
In a recent paper, scientists targeted a small, harmful piece of the huntingtin message (HTT1a) in HD mice. This reduced toxic protein clumps and delayed genetic changes, more than targeting full length HTT.
-
Tagging the Trash: Turnover of Toxic Huntingtin
5 min read
A recent study suggests that strengthening the brain’s own clean-up system could slow Huntington’s disease.
-
Prilenia’s Application for European Approval of Pridopidine Withdrawn
4 min read
Prilenia’s application for European approval of pridopidine was quietly withdrawn 6 months ago, in November 2025, after the EMA had already recommended refusing the drug. Here’s what happened, and why you’re only hearing about it now.
-
Intruders in the Brain: What a Pig Model Reveals about Immune Cells in HD
7 min read
A recent study in pigs suggests the HD brain could be under attack from the body’s own immune system. The results reveal that invading cytotoxic T cells might contribute to neurodegeneration in HD, suggesting a new therapeutic pathway.
-
The Great Care Conundrum: What “Good” Care Looks Like in Huntington’s Disease
8 min read
What does “good care” look like in Huntington’s Disease? A new Dutch study asked familial and professional caregivers, and uncovered how differently it’s experienced in practice.
-
A Second Path: uniQure Plans Regulatory Filing for AMT-130 in the UK
5 min read
While the US regulatory path for AMT-130 remains complicated, uniQure announced plans to seek approval for its HD gene therapy in the UK. Here’s what that means, and what might be to come.
-
Two Years In: New Long-Term Extension Data from PIVOT-HD for Votoplam
9 min read
PTC Therapeutics shared 2-year data for votoplam, a daily HTT-lowering pill. Stage 2 participants showed up to 52% slowing of disease progression. Here’s what the data show, what’s still missing, and the roll out of the Phase 3 trial.
-
April 2026: This Month in Huntington’s Disease Research
8 min read
April 2026 showed us a toxic HTT fragment is center stage in mouse research, CRISPR is showing promise in mouse studies, AI and wearables move closer to the clinic, and 2 studies shine a light on the weight carried by HD caregivers.
-
The Number on the Scale: What the TFC Score Measures, and Why It Matters Right Now
9 min read
The Total Functional Capacity score has been used in Huntington’s disease research for decades. Here’s what it measures, what it misses, & why it’s at the center of an anticipated clinical trial.
-
Dancing With a Stranger: Understanding Apathy in Huntington’s Disease Through Caregivers
5 min read
Apathy in HD isn’t just “not caring.” It can affect relationships, routines, and emotional connection. A small study of caregivers reveals the heavy toll of apathy and the value of safe spaces to share experiences.
HDBuzz Trial Tracker
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
